Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

Background: Rituximab is commonly used for systemic lupus erythematosus (SLE) but secondary non-depletion and non-response (2NDNR) associated with anti-drug antibodies is a notable problem with repeat rituximab cycles. Other B cell-targeted therapies include other anti-CD20 monoclonal antibodies or...

Full description

Bibliographic Details
Main Authors: Sabih Ul Hassan, Md Yuzaiful Md Yusof, Paul Emery, Shouvik Dass, Edward M. Vital
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Medicine
Subjects:
B cells
belimumab
immunogenecity
rituximab
systemic lupus erythematosus
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2020.00498/full

Internet

https://www.frontiersin.org/article/10.3389/fmed.2020.00498/full

Similar Items